Senestech (NASDAQ:SNES – Get Free Report) is one of 296 publicly-traded companies in the “Chemicals” industry, but how does it weigh in compared to its peers? We will compare Senestech to similar companies based on the strength of its profitability, earnings, dividends, institutional ownership, analyst recommendations, risk and valuation.
Profitability
This table compares Senestech and its peers’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Senestech | -275.26% | -88.62% | -62.01% |
| Senestech Competitors | -54.13% | -0.60% | -1.36% |
Earnings & Valuation
This table compares Senestech and its peers top-line revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Senestech | $2.78 million | -$6.38 million | -0.59 |
| Senestech Competitors | $6.37 billion | $229.42 million | 19.87 |
Senestech’s peers have higher revenue and earnings than Senestech. Senestech is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Institutional & Insider Ownership
5.2% of Senestech shares are owned by institutional investors. Comparatively, 47.4% of shares of all “Chemicals” companies are owned by institutional investors. 2.2% of Senestech shares are owned by insiders. Comparatively, 13.7% of shares of all “Chemicals” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Analyst Ratings
This is a summary of recent recommendations and price targets for Senestech and its peers, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Senestech | 1 | 0 | 0 | 0 | 1.00 |
| Senestech Competitors | 3273 | 12243 | 14159 | 521 | 2.40 |
As a group, “Chemicals” companies have a potential upside of 7.61%. Given Senestech’s peers stronger consensus rating and higher possible upside, analysts clearly believe Senestech has less favorable growth aspects than its peers.
Volatility & Risk
Senestech has a beta of 0.11, meaning that its stock price is 89% less volatile than the S&P 500. Comparatively, Senestech’s peers have a beta of 1.09, meaning that their average stock price is 9% more volatile than the S&P 500.
Summary
Senestech peers beat Senestech on 13 of the 13 factors compared.
About Senestech
SenesTech, Inc. is a biotechnology company focused on developing fertility-control technologies for managing animal populations. The company’s approach is designed to reduce reproduction rather than rely solely on lethal control methods, with applications primarily in rodent management. SenesTech’s principal product is ContraPest, a liquid bait designed to reduce fertility in rats by affecting reproductive function in both male and female animals. The product is intended for use in commercial, municipal and other settings where rat populations pose sanitation, health or property risks.
Receive News & Ratings for Senestech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Senestech and related companies with MarketBeat.com's FREE daily email newsletter.
